Overview
The Tirzepatide 40mg vial is Nova Biolabs' largest offering of this dual GLP-1/GIP receptor agonist, providing outstanding value per milligram for high-volume research applications. Stored in UK domestic stock and dispatched with the same fast, discreet service as all Nova Biolabs products.
Tirzepatide's twin-receptor mechanism — simultaneously engaging both GLP-1 and GIP receptors — makes it one of the most pharmacologically interesting compounds in current metabolic research, and the 40mg vial gives research teams the volume to conduct comprehensive studies.
Key Research Areas
High-Volume Laboratory Research
The 40mg vial provides sufficient compound for extended research programmes, multi-arm studies, or shared use across research team members.
GLP-1 and GIP Dual-Receptor Studies
The compound's unique dual mechanism continues to make it a focus of receptor pharmacology research globally, particularly in metabolic and endocrine research.
Longitudinal Metabolic Studies
Suitable for studies requiring consistent compound access over extended timeframes without the need for repeat ordering.
Cellular Signalling Research
Used in pancreatic, hepatic, and adipose tissue cell line models to investigate downstream signalling cascades from dual incretin receptor activation.
Product Specifications
| Format | Lyophilised powder |
| Quantity | 40mg per vial |
| Purity | >98% (HPLC verified) |
| Storage | Refrigerate at 2–8°C. Stable 24 months lyophilised. |
| Origin | UK domestic stock |
| Research use | In vitro / laboratory use only |